FLC
NBSE

Fifth Lane Capital’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Fifth Lane Capital’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$56K – 377
2021
Q4 		$56K Buy
+1,000
New +$67.1K 0.03% 186

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Fifth Lane Capital's NBSE Position: Q1 2022 in Review

Fifth Lane Capital sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2022, closing a stake of 1,000 shares — an estimated $56K sold.

Fifth Lane Capital first reported a position in NBSE in Q4 2021 and held it in 1 quarter. The position peaked at $56K in Q4 2021. 45 funds tracked by Wall St. Rank hold NBSE as of Q1 2022.

  • Fifth Lane Capital reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Fifth Lane Capital sold 1,000 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $56K.
  • Fifth Lane Capital first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Fifth Lane Capital's NeuBase Therapeutics, Inc. Common Stock position peaked at $56K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Fifth Lane Capital's 13F filing for Q1 2022, filed 16 May 2022.